April 17, 2003
Refractec Completes Phase III Presbyopia Clinical Trial Enrollment
Cataract & Refractive Syrgery Today April 2003
Refractec, Inc. (Irvine, CA), has completed patient enrollment for its FDA Phase III clinical trial evaluating Conductive Keratoplasty (CK) for the treatment of presbyopia. Recent data from the 160-eye CK presbyopia trial show that, at 12 months, 97% of the patients could see 20/20 at distance and read magazine- and newspaper-sized print; 75% could see 20/20 and read J2 at near; and 96% reported being “satisfied” to “very satisfied” with their outcome. The company plans to file for premarket approval later this year.
Posted by mehdi khanlari at April 17, 2003 04:59 PM